Natural products in traditional Chinese medicine: molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems - 05/01/24
, Song-qi Tang c, ⁎ , Wei Huang a, ⁎ Abstract |
Renal fibrosis (RF) is the end stage of several chronic kidney diseases. Its series of changes include excessive accumulation of extracellular matrix, epithelial-mesenchymal transition (EMT) of renal tubular cells, fibroblast activation, immune cell infiltration, and renal cell apoptosis. RF can eventually lead to renal dysfunction or even renal failure. A large body of evidence suggests that natural products in traditional Chinese medicine (TCM) have great potential for treating RF. In this article, we first describe the recent advances in RF treatment by several natural products and clarify their mechanisms of action. They can ameliorate the RF disease phenotype, which includes apoptosis, endoplasmic reticulum stress, and EMT, by affecting relevant signaling pathways and molecular targets, thereby delaying or reversing fibrosis. We also present the roles of nanodrug delivery systems, which have been explored to address the drawback of low oral bioavailability of natural products. This may provide new ideas for using natural products for RF treatment. Finally, we provide new insights into the clinical prospects of herbal natural products.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Fig. 1. Pectolinarigenin; PUE: Puerarin; QUE: Quercetin; ISL: Isoliquiritigenin; CA: Calycosin; DHM: Dihydromyricetin; API: Apigenin; DHQ: Dihydroquercetin; TS IIA: Tanshinone IIA; RH: Rhein; EMD: Emodin; CP: Chrysophanol; CUR: Curcumin; RSV: Resveratrol; SAB: Salvianolic acid B; EGCG: Epigallocatechin-3-Gallate; SAL: Salidroside; AS IV: Astragaloside IV; Rg1: Ginsenoside Rg1; BBR: Berberine; OM: Oxymatrine; SIN: Sinomenine; DHA: Dihydroartemisinin; ART: Artemisinin; GAA: Ganoderic acid A; TP: Triptolide; PAA: Poricoic acid A.
Fig. 1. Pectolinarigenin; PUE: Puerarin; QUE: Quercetin; ISL: Isoliquiritigenin; CA: Calycosin; DHM: Dihydromyricetin; API: Apigenin; DHQ: Dihydroquercetin; TS IIA: Tanshinone IIA; RH: Rhein; EMD: Emodin; CP: Chrysophanol; CUR: Curcumin; RSV: Resveratrol; SAB: Salvianolic acid B; EGCG: Epigallocatechin-3-Gallate; SAL: Salidroside; AS IV: Astragaloside IV; Rg1: Ginsenoside Rg1; BBR: Berberine; OM: Oxymatrine; SIN: Sinomenine; DHA: Dihydroartemisinin; ART: Artemisinin; GAA: Ganoderic acid A; TP: Triptolide; PAA: Poricoic acid A.ga1Le texte complet de cet article est disponible en PDF.
Highlights |
• | There is abundant evidence that natural products of Chinese medicines have reversal or delaying effects on renal fibrosis. |
• | Natural products can play therapeutic roles in treating various causes of renal fibrosis through different signaling pathways. |
• | Nano-delivery systems can help address the low bioavailability of natural products, making the treatment of renal fibrosis with Chinese medicine more promising. |
Chemical compounds studied in this article : Pectolinarigenin (Pubmed CID: 5320438), Puerarin (Pubmed CID: 5281807), Quercetin (Pubmed CID: 5280343), Isoliquiritigenin (Pubmed CID: 638278), Calycosin (Pubmed CID: 5280448)；Dihydromyricetin (Pubmed CID: 161557), Apigenin (Pubmed CID: 5280443), Dihydroquercetin (Pubmed CID: 439533), Tanshinone IIA (Pubmed CID: 164676), Rhein (Pubmed CID: 10168), Emodin (Pubmed CID: 3220), Chrysophanol (Pubmed CID: 10208), Curcumin (Pubmed CID: 969516), Resveratrol (Pubmed CID: 445154), Salvianolic acid B (Pubmed CID: 6541084), Epigallocatechin-3-Gallate (Pubmed CID: 65064), Salidroside (Pubmed CID: 159278), Astragaloside IV (Pubmed CID: 13943297), Ginsenoside Rg1 (Pubmed CID: 441923), Berberine (Pubmed CID: 2353), Oxymatrine (Pubmed CID: 114850)
Abbreviations : RF, CDK, ECM, TCM, ERS, JAK, STAT, MAPK, PI3K, ROS, EMT, FSP-1, HSP 47, Col1α1, PDGFRβ, PDGFRα, MEG3, COLEC11, CXCL12, RGS5, TGF-β, HER2, CTGF, TIMP, LCN2, INHBB, α-SMA, FN, TNC, RAS, SGLT2, GLP-1, ET-1, NRF2, NF-κB, TLR4, MyD88, IRF5, SIRT1, PINK1, Syk, IL-33, ST2, TNFR1, NOX2, HO-1, URAT1, GLUT9, TRPV4, TNF-α, AMPK, ERK1/2, NLRP3, MCP-1, PERK, elF2a, ATF4, SHH, Gli1, PPARα, CPTIa, ACOX1, Bcl-2, Bax, STRT1, CREB, BMP, mTOR, HGF, Smurf2, HMGA2, EZH2, NKD2, Cav-1, Keap 1, APPL1, LC3 II, RGMb, SphK1, S1P, foxo3a, HPSE, PDGF-C, GSK-3β, ACTN4, VEGF, DNMT, PGC1-α, Cx43, mTORC1, TSP-1, TRPC6, NFAT2, MMP2, RhoA, ROCK, P2×7R, MDM2, DUSP6, SnoN, Id2, LN, IL-6, ICAM-1, SOCS1, DNMT1, TRX, TRXR, PTEN, TPH-1, UUO, HEK293, NRK-49 F, cAMP, HK-2, RTEC, DN, COL III, HFD, STZ, BMSC, PTEC, NADPH, DKD, VDR, HG, NRK-52E, ConA, C3aR, C5aR, suPAR, h3k27me3, FA, RSK2, T2DM, MN, TGFR, AKI, JNK, SAPK, cPLA2, EGFR, CTMP, NDSS, SLN, CS
Keywords : Renal fibrosis, Natural products, Flavonoids, Phenols, NDSS
Plan
Vol 170
Article 116039- janvier 2024 Retour au numéro
Article précédent
- Macrophage fatty acid oxidation in atherosclerosis
- Sujun Xiao, Mingxu Qi, Qinyi Zhou, Huiqin Gong, Duhui Wei, Guangneng Wang, Qilun Feng, Zhou Wang, Zhe Liu, Yiren Zhou, Xiaofeng Ma
- Ferroptosis in cardiovascular disease
- Guoqing Liu, Xiaoyong Xie, Wang Liao, Siyuan Chen, Rumao Zhong, Jiahui Qin, Peichun He, Jian Xie
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?